Physician profile
Gitane Patel
NPI 1710171434
$9,823.67
in general payments reported to CMS, 2019-2025
28 companies · $2,174 in 2025
The $2,174 reported for 2025 was more than what 89% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,371 · 2020: $660 · 2021: $1,143 · 2022: $2,326 · 2023: $902 · 2024: $1,248 · 2025: $2,174.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,325.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,324.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,909.75 | 2019-2025 | Rocklatan, Tryptyr, Clareon Panoptix Pro |
| Oyster Point Pharma, INC. | $819.89 | 2022-2025 | Tyrvaya |
| Sun Pharmaceutical Industries INC. | $601.39 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $596.06 | 2019-2023 | |
| Eyevance Pharmaceuticals LLC | $585.84 | 2019-2022 | |
| New World Medical,INC. | $567.41 | 2022-2023 | |
| Bausch & Lomb Americas INC. | $537.44 | 2022-2025 | Miebo, Xiidra, Envista Envy Iol |
| Glaukos Corporation | $510.23 | 2023-2024 | Idose |
| Tarsus Pharmaceuticals, INC. | $472.41 | 2024-2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $445.78 | 2019-2021 | |
| Aerie Pharmaceuticals, INC. | $425.37 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $405.25 | 2020-2022 | |
| Mallinckrodt Hospital Products INC. | $335.70 | 2020-2025 | Acthar |
| Dompe US, INC. | $333.06 | 2024-2025 | Oxervate |
| Horizon Therapeutics Plc | $176.09 | 2021-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $160.00 | 2020-2022 | |
| Harrow Eye, LLC | $156.95 | 2025 | Vevye |
| Abbvie INC. | $147.62 | 2022-2025 | |
| Amgen INC. | $125.42 | 2025 | Tepezza |
| Rxsight INC | $125.00 | 2025 | Rxsight Contact Lens, Light Adjustable Lens (Lal), Rxsight Injector Cartridge |
| Teva Pharmaceuticals USA, INC. | $124.88 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $117.86 | 2021 | |
| Shire North American Group INC | $36.97 | 2019 | |
| Sight Sciences, INC. | $36.03 | 2024 | Omni Surgical System |
| Biohaven Pharmaceutical Holding Company Ltd. | $23.52 | 2022 | |
| Thea Pharma INC. | $18.15 | 2025 | Iyuzeh |
| Beaver-Visitec International, INC. | $17.92 | 2021 | |
| Omeros Corporation | $11.68 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gitane Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.